Actively Recruiting
CATALINA-4 Phase 1B2 Study of TORL-1-23 With Chemotherapy Before Surgery in Women with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Led by TORL Biotherapeutics, LLC · Updated on 2026-07-13
60
Participants Needed
7
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety and effectiveness of TORL-1-23 combined with chemotherapy given before initial surgery in women with advanced stage ovarian cancer, including fallopian tube and primary peritoneal cancers. The study focuses on patients with FIGO Stage III or IV disease who express claudin 6 CLDN6. It is a Phase 1B2 clinical trial sponsored by TORL Biotherapeutics, LLC, designed to explore treatment options before surgery in this population. Participants receive one of three experimental treatment combinations TORL-1-23 with paclitaxel, TORL-1-23 with carboplatin, or TORL-1-23 with paclitaxel and carboplatin. Each treatment is given once every three weeks in cycles, with the main treatment phase lasting up to 8 cycles. The treatments are administered before interval cytoreductive surgery, and the study monitors both safety and effectiveness during and after these cycles. Throughout the study, participants are closely monitored for adverse events and treatment tolerability, with specific safety assessments from Cycle 1 to Cycle 4 and efficacy evaluations after Cycle 4 following surgery. Researchers also track the duration of treatment benefit for up to 15 months post-surgery. The trial includes evaluations of organ function and performance status to ensure participant safety and study integrity.
CONDITIONS
Brief Title
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Research Team
C
Caroline Labib, PharmD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here